December 1, 1996Journal of Lipid ResearchOpen Access

Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease

View Full Paper

Ask AI

Bookmark

Population

19 Caucasian patients with familial combined hyperlipidemia and reduced post-heparin plasma LPL levels, 115…

Design

Cross-sectional

Authors

WYWei‐Shiung YangNational Taiwan University DNDavid NevinUniversity of the Witwatersrand LILori IwasakiCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Discussion

Member takes

Implication

Promoter variants may contribute to FCHL dyslipidemia; hypothesis-generating and requires validation before any clinical application.

Structured PICO

Population

19 Caucasian patients with familial combined hyperlipidemia (FCHL) and reduced post-heparin plasma LPL levels, 115 CAD patients, and 183 unselected Caucasian subjects. In vitro models: THP-1 (macrophage-like) and C2C12 (myotube-like) cells.

Outcome

LPL promoter activitysurrogate

Regulatory mutations in the LPL gene promoter (-39 and -53) found in FCHL patients significantly decrease promoter activity, suggesting a role in the development of dyslipidemia in FCHL.

Cite This Study

Yang et al. (1996) studied this question.

synapsesocial.com/papers/6a7170ea6c240de38cdc2417 https://doi.org/10.1016/s0022-2275(20)37466-6

View Full Paper

Ask AI

Bookmark

Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider